Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized non-inferiority trial of dolutegravir + lamivudine maintenance therapy in virologically suppressed children with HIV
2024-520388-15-00Phase 3Completed
- Sponsor
- Penta Foundation
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of dolutegravir + lamivudine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Penta Foundation. Primary endpoint: Confirmed viral rebound by week 96. Started Jun 2023; status: completed.
02
Drugs
dolutegravir + lamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2024-520388-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520388-15-00.